RecruitingNot ApplicableNCT06406166

Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Clinical Efficacy of Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Sponsor

Henan University of Traditional Chinese Medicine

Enrollment

100 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Non-Small Cell Lung Cancer

Summary

This study is to evaluate the clinical efficacy of Lifei Xiaoji Wan for advanced non-small cell lung cancer (NSCLC), establish the treatment scheme, and obtain high-quality clinical evidence.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying a traditional Chinese herbal medicine called Lifei Xiaoji Wan to see if it can benefit patients with advanced non-small cell lung cancer (NSCLC) who are on immunotherapy or standard treatment. The study is looking at quality of life, symptom management, and survival outcomes. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with NSCLC (non-small cell lung cancer) at Stage III or IV - Your expected survival is more than 3 months **You may NOT be eligible if...** - You had early-stage NSCLC that was successfully treated with surgery and has not recurred - You have serious problems with your heart, liver, kidneys, or other vital organs - You have a mental illness or other condition that would prevent you from completing the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLifei Xiaoji Wan

The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on

OTHERConventional treatment with Western medicine

Conventional treatment with Western medicine

Locations(1)

the First Affiliated Hospital of Henan University of Chinese Medicine

Zhengzhou, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06406166

Related Trials

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

NCT076527361 location

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT0509917294 locations

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596770 locations

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT021331961 location

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT0718599774 locations